SALE
市場調查報告書

白血病治療的全球市場:2025年為止的預測與市場機會

Global Leukemia Therapeutics Market By Factor, By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment, By Diagnosis, By Route of Administration, By Drugs, By Region, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 938725
出版日期 內容資訊 英文 110 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

白血病治療的全球市場:2025年為止的預測與市場機會 Global Leukemia Therapeutics Market By Factor, By Severity, By Blood Cell, By Age Groups, By Sex, By Treatment, By Diagnosis, By Route of Administration, By Drugs, By Region, Forecast & Opportunities, 2025
出版日期: 2020年05月01日內容資訊: 英文 110 Pages
簡介

全球白血病治療市場在預測期間內預計將穩定增長。市場成長的主要因素有受白血病所苦的患者增加,血癌檢驗領域的技術進步與創新。此外,人們對採用預防保健的認識的提高以及政府對癌症認識的支持性工作和政策有望在2025年之前推動市場增長。

本報告提供各市場區隔和各地區的全球白血病治療市場調查,提供市場規模及市場佔有率的預測,推動因素與課題,市場趨勢,競爭情形,企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 客戶的迴響

第5章 全球白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別(人工電離放射線,病毒,化療,遺傳學,免疫抑制,其他)
    • 重症度別(急性,慢性)
    • 各血液細胞(淋巴球性,骨髓性)
    • 各年齡層(0-15,15-30,30-50,50 +)
    • 性別(男性,女性)
    • 不同治療(標靶治療,干擾素療法,放射線治療,手術,幹細胞移植,藥物,基因治療,免疫療法,疫苗療法,化療,輸血)
    • 各診斷(血液檢驗,切片檢查,身體檢查,影像檢查(CT-SCAN,X-RAY,MRI))
    • 各給藥途徑(口服,靜脈內,皮下,肌肉內,髓腔裡面)
    • 各藥物抗代謝物,生物仿製藥,天冬酰胺特異性酶,激素(皮質類固醇),次甲基化(去甲基化)劑,酪氨酸激酶抑製劑等)
    • 各公司
    • 各地區
  • 市場魅力指數

第6章 亞太地區的白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別
    • 重症度別
    • 各血液細胞
    • 各年齡
    • 性別
    • 不同治療
    • 各診斷
    • 各給藥途徑
    • 各藥物
    • 各國
  • 市場魅力指數
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 澳洲

第7章 歐洲的白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別
    • 重症度別
    • 各血液細胞
    • 各年齡
    • 性別
    • 不同治療
    • 各診斷
    • 各給藥途徑
    • 各藥物
    • 各國
  • 市場魅力指數
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利

第8章 北美的白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別
    • 重症度別
    • 各血液細胞
    • 各年齡
    • 性別
    • 不同治療
    • 各診斷
    • 各給藥途徑
    • 各藥物
    • 各國
  • 市場魅力指數
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章 南美的白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別
    • 重症度別
    • 各血液細胞
    • 各年齡
    • 性別
    • 不同治療
    • 各診斷
    • 各給藥途徑
    • 各藥物
    • 各國
  • 市場魅力指數
  • 南美:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 中東·非洲的白血病治療市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 要因別
    • 重症度別
    • 各血液細胞
    • 各年齡
    • 性別
    • 不同治療
    • 各診斷
    • 各給藥途徑
    • 各藥物
    • 各國
  • 市場魅力指數
  • 中東·非洲:國家分析
    • 南非
    • 沙烏地阿拉伯
    • UAE

第11章 市場動態

  • 促進因素
  • 課題

第12章 市場趨勢與發展

第13章 競爭情形

  • 競爭的展望
  • 主要企業簡介
    • Novartis
    • AbbVie
    • Bristol-Myers Squibb
    • Roche
    • Amgen
    • Gilead sciences
    • Celgene
    • Eisai
    • AstraZeneca
    • Incyte Corporation
    • Johnson & Johnson
    • Biogen
    • Merck
    • PerkinElmer
    • Eli Lilly
    • Abbott
    • Sumitomo Dainippon Pharma
    • Thermo Fisher Scientific
    • Otsuka Holdings
    • Astellas Pharma

第14章 策略性推薦事項

第15章 免責聲明

目錄
Product Code: 4534

Leukemia or blood cancer is the cancer of blood forming tissues: bone marrow and lymphatic system. As the name suggests, it affects the leucocytes or white blood cells. In this type of cancer, the DNA of leucocytes gets damaged as a result of which they grow and divide uncontrollably. These cells keep on growing and start accumulating, thereby preventing the healthy white blood cells from growing and functioning.

Global leukemia therapeutics market is expected to grow at a formidable rate during the forecast period. The global leukemia therapeutics market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Furthermore, supportive government initiatives & policies for promoting cancer awareness is anticipated to fuel the market growth until 2025.

The global leukemia therapeutics market can be segmented based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and region. Based on severity, the market can be bifurcated into acute and chronic. The chronic leukemia segment is expected to dominate the market during forecast period. This can be accredited to the rising geriatric population and increasing funding for cancer research and the development of new therapies.

Regionally, the leukemia therapeutics market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market during forecast period. This can be attributed to the presence of a large geriatric population base in the country. Additionally, the presence of key players in the region is further expected to propel the market over 2025.

Major players operating in the global leukemia therapeutics market include Novartis, AbbVie, Bristol-Myers Squibb, Roche, Amgen, Gilead sciences, Celgene, Eisai, AstraZeneca, Incyte Corporation, Johnson & Johnson, Biogen, Merck, PerkinElmer, Eli Lilly, Abbott, Sumitomo Dainippon Pharma, Thermo Fisher Scientific, Otsuka Holdings, Astellas Pharma and others. The companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share. For instance, in August 2017, Bristol-Myers Squibb acquired IFM Therapeutics in order to fortify its oncology product line.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and forecast the market size of global leukemia therapeutics market.
  • To classify and forecast global leukemia therapeutics market based on factor, severity, blood cell, age groups, sex, treatment, diagnosis, route of administration, drugs, company and regional distribution.
  • To identify drivers and challenges for global leukemia therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global leukemia therapeutics market.
  • To identify and analyze the profile of leading players operating in global leukemia therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global leukemia therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Leukemia therapeutics manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to leukemia therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global leukemia therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Factor:

Artificial ionizing radiation

Viruses

Chemotherapy

Genetics

Immune suppression

Others

  • Market, By Severity:

Acute

Chronic

  • Market, By Blood Cell:

Lymphocytic

Myelogenous

  • Market, By Age Groups:

0-15

15-30

30-50

50+

  • Market, By Sex:

Male

Female

  • Market, By Treatment:

Targeted Therapy

Interferon Therapy

Radiation Therapy

Surgery

Stem Cell Transplantation

Drugs

Gene Therapy

Immunotherapy

Vaccine Therapy

Chemotherapy

Blood Transfusion

  • Market, By Diagnosis:

Blood test

Biopsy

Physical Exam

Imagining

  • CT-SCAN
  • X-RAY
  • MRI
  • Market, By Route of Administration:

Oral

Intravenous

Subcutaneous

Intramuscular

Intrathecal

  • Market, By Drugs:

Antimetabolites

Biosimilars

Asparagine-Specific Enzymes

Hormones (Corticosteroids)

Hypomethylating (Demethylating) Agents

Tyrosine Kinase Inhibitors

Others

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global leukemia therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Leukemia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Factor (Artificial ionizing radiation, Viruses, Chemotherapy, Genetics, Immune suppression, Others)
    • 5.2.2. By Severity (Acute, Chronic)
    • 5.2.3. By Blood Cell (Lymphocytic, Myelogenous)
    • 5.2.4. By Age Groups (0-15, 15-30, 30-50, 50+)
    • 5.2.5. By Sex (Male, Female)
    • 5.2.6. By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Surgery, Stem Cell Transplantation, Drugs, Gene Therapy, Immunotherapy, Vaccine Therapy, Chemotherapy, Blood Transfusion)
    • 5.2.7. By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining (CT-SCAN, X-RAY, MRI))
    • 5.2.8. By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal)
    • 5.2.9. By Drugs (Antimetabolites, Biosimilars, Asparagine-Specific Enzymes, Hormones (Corticosteroids), Hypomethylating (Demethylating) Agents, Tyrosine Kinase Inhibitors, Others)
    • 5.2.10. By Company (2019)
    • 5.2.11. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Leukemia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Factor
    • 6.2.2. By Severity
    • 6.2.3. By Blood Cell
    • 6.2.4. By Age Groups
    • 6.2.5. By Sex
    • 6.2.6. By Treatment
    • 6.2.7. By Diagnosis
    • 6.2.8. By Route of Administration
    • 6.2.9. By Drugs
    • 6.2.10. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Leukemia Therapeutics Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Factor
        • 6.4.1.2.2. By Severity
        • 6.4.1.2.3. By Blood Cell
        • 6.4.1.2.4. By Age Groups
        • 6.4.1.2.5. By Sex
        • 6.4.1.2.6. By Treatment
        • 6.4.1.2.7. By Diagnosis
        • 6.4.1.2.8. By Route of Administration
        • 6.4.1.2.9. By Drugs
    • 6.4.2. India Leukemia Therapeutics Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Factor
        • 6.4.2.2.2. By Severity
        • 6.4.2.2.3. By Blood Cell
        • 6.4.2.2.4. By Age Groups
        • 6.4.2.2.5. By Sex
        • 6.4.2.2.6. By Treatment
        • 6.4.2.2.7. By Diagnosis
        • 6.4.2.2.8. By Route of Administration
        • 6.4.2.2.9. By Drugs
    • 6.4.3. Japan Leukemia Therapeutics Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Factor
        • 6.4.3.2.2. By Severity
        • 6.4.3.2.3. By Blood Cell
        • 6.4.3.2.4. By Age Groups
        • 6.4.3.2.5. By Sex
        • 6.4.3.2.6. By Treatment
        • 6.4.3.2.7. By Diagnosis
        • 6.4.3.2.8. By Route of Administration
        • 6.4.3.2.9. By Drugs
    • 6.4.4. South Korea Leukemia Therapeutics Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Factor
        • 6.4.4.2.2. By Severity
        • 6.4.4.2.3. By Blood Cell
        • 6.4.4.2.4. By Age Groups
        • 6.4.4.2.5. By Sex
        • 6.4.4.2.6. By Treatment
        • 6.4.4.2.7. By Diagnosis
        • 6.4.4.2.8. By Route of Administration
        • 6.4.4.2.9. By Drugs
    • 6.4.5. Singapore Leukemia Therapeutics Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Factor
        • 6.4.5.2.2. By Severity
        • 6.4.5.2.3. By Blood Cell
        • 6.4.5.2.4. By Age Groups
        • 6.4.5.2.5. By Sex
        • 6.4.5.2.6. By Treatment
        • 6.4.5.2.7. By Diagnosis
        • 6.4.5.2.8. By Route of Administration
        • 6.4.5.2.9. By Drugs
    • 6.4.6. Australia Leukemia Therapeutics Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Factor
        • 6.4.6.2.2. By Severity
        • 6.4.6.2.3. By Blood Cell
        • 6.4.6.2.4. By Age Groups
        • 6.4.6.2.5. By Sex
        • 6.4.6.2.6. By Treatment
        • 6.4.6.2.7. By Diagnosis
        • 6.4.6.2.8. By Route of Administration
        • 6.4.6.2.9. By Drugs

7. Europe Leukemia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Factor
    • 7.2.2. By Severity
    • 7.2.3. By Blood Cell
    • 7.2.4. By Age Groups
    • 7.2.5. By Sex
    • 7.2.6. By Treatment
    • 7.2.7. By Diagnosis
    • 7.2.8. By Route of Administration
    • 7.2.9. By Drugs
    • 7.2.10. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Leukemia Therapeutics Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Factor
        • 7.4.1.2.2. By Severity
        • 7.4.1.2.3. By Blood Cell
        • 7.4.1.2.4. By Age Groups
        • 7.4.1.2.5. By Sex
        • 7.4.1.2.6. By Treatment
        • 7.4.1.2.7. By Diagnosis
        • 7.4.1.2.8. By Route of Administration
        • 7.4.1.2.9. By Drugs
    • 7.4.2. Germany Leukemia Therapeutics Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Factor
        • 7.4.2.2.2. By Severity
        • 7.4.2.2.3. By Blood Cell
        • 7.4.2.2.4. By Age Groups
        • 7.4.2.2.5. By Sex
        • 7.4.2.2.6. By Treatment
        • 7.4.2.2.7. By Diagnosis
        • 7.4.2.2.8. By Route of Administration
        • 7.4.2.2.9. By Drugs
    • 7.4.3. United Kingdom Leukemia Therapeutics Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Factor
        • 7.4.3.2.2. By Severity
        • 7.4.3.2.3. By Blood Cell
        • 7.4.3.2.4. By Age Groups
        • 7.4.3.2.5. By Sex
        • 7.4.3.2.6. By Treatment
        • 7.4.3.2.7. By Diagnosis
        • 7.4.3.2.8. By Route of Administration
        • 7.4.3.2.9. By Drugs
    • 7.4.4. Italy Leukemia Therapeutics Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Factor
        • 7.4.4.2.2. By Severity
        • 7.4.4.2.3. By Blood Cell
        • 7.4.4.2.4. By Age Groups
        • 7.4.4.2.5. By Sex
        • 7.4.4.2.6. By Treatment
        • 7.4.4.2.7. By Diagnosis
        • 7.4.4.2.8. By Route of Administration
        • 7.4.4.2.9. By Drugs

8. North America Leukemia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Factor
    • 8.2.2. By Severity
    • 8.2.3. By Blood Cell
    • 8.2.4. By Age Groups
    • 8.2.5. By Sex
    • 8.2.6. By Treatment
    • 8.2.7. By Diagnosis
    • 8.2.8. By Route of Administration
    • 8.2.9. By Drugs
    • 8.2.10. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Leukemia Therapeutics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Factor
        • 8.4.1.2.2. By Severity
        • 8.4.1.2.3. By Blood Cell
        • 8.4.1.2.4. By Age Groups
        • 8.4.1.2.5. By Sex
        • 8.4.1.2.6. By Treatment
        • 8.4.1.2.7. By Diagnosis
        • 8.4.1.2.8. By Route of Administration
        • 8.4.1.2.9. By Drugs
    • 8.4.2. Mexico Leukemia Therapeutics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Factor
        • 8.4.2.2.2. By Severity
        • 8.4.2.2.3. By Blood Cell
        • 8.4.2.2.4. By Age Groups
        • 8.4.2.2.5. By Sex
        • 8.4.2.2.6. By Treatment
        • 8.4.2.2.7. By Diagnosis
        • 8.4.2.2.8. By Route of Administration
        • 8.4.2.2.9. By Drugs
    • 8.4.3. Canada Leukemia Therapeutics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Factor
        • 8.4.3.2.2. By Severity
        • 8.4.3.2.3. By Blood Cell
        • 8.4.3.2.4. By Age Groups
        • 8.4.3.2.5. By Sex
        • 8.4.3.2.6. By Treatment
        • 8.4.3.2.7. By Diagnosis
        • 8.4.3.2.8. By Route of Administration
        • 8.4.3.2.9. By Drugs

9. South America Leukemia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Factor
    • 9.2.2. By Severity
    • 9.2.3. By Blood Cell
    • 9.2.4. By Age Groups
    • 9.2.5. By Sex
    • 9.2.6. By Treatment
    • 9.2.7. By Diagnosis
    • 9.2.8. By Route of Administration
    • 9.2.9. By Drugs
    • 9.2.10. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Leukemia Therapeutics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Factor
        • 9.4.1.2.2. By Severity
        • 9.4.1.2.3. By Blood Cell
        • 9.4.1.2.4. By Age Groups
        • 9.4.1.2.5. By Sex
        • 9.4.1.2.6. By Treatment
        • 9.4.1.2.7. By Diagnosis
        • 9.4.1.2.8. By Route of Administration
        • 9.4.1.2.9. By Drugs
    • 9.4.2. Argentina Leukemia Therapeutics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Factor
        • 9.4.2.2.2. By Severity
        • 9.4.2.2.3. By Blood Cell
        • 9.4.2.2.4. By Age Groups
        • 9.4.2.2.5. By Sex
        • 9.4.2.2.6. By Treatment
        • 9.4.2.2.7. By Diagnosis
        • 9.4.2.2.8. By Route of Administration
        • 9.4.2.2.9. By Drugs
    • 9.4.3. Colombia Leukemia Therapeutics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Factor
        • 9.4.3.2.2. By Severity
        • 9.4.3.2.3. By Blood Cell
        • 9.4.3.2.4. By Age Groups
        • 9.4.3.2.5. By Sex
        • 9.4.3.2.6. By Treatment
        • 9.4.3.2.7. By Diagnosis
        • 9.4.3.2.8. By Route of Administration
        • 9.4.3.2.9. By Drugs

10. Middle East and Africa Leukemia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Factor
    • 10.2.2. By Severity
    • 10.2.3. By Blood Cell
    • 10.2.4. By Age Groups
    • 10.2.5. By Sex
    • 10.2.6. By Treatment
    • 10.2.7. By Diagnosis
    • 10.2.8. By Route of Administration
    • 10.2.9. By Drugs
    • 10.2.10. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Leukemia Therapeutics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Factor
        • 10.4.1.2.2. By Severity
        • 10.4.1.2.3. By Blood Cell
        • 10.4.1.2.4. By Age Groups
        • 10.4.1.2.5. By Sex
        • 10.4.1.2.6. By Treatment
        • 10.4.1.2.7. By Diagnosis
        • 10.4.1.2.8. By Route of Administration
        • 10.4.1.2.9. By Drugs
    • 10.4.2. Saudi Arabia Leukemia Therapeutics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Factor
        • 10.4.2.2.2. By Severity
        • 10.4.2.2.3. By Blood Cell
        • 10.4.2.2.4. By Age Groups
        • 10.4.2.2.5. By Sex
        • 10.4.2.2.6. By Treatment
        • 10.4.2.2.7. By Diagnosis
        • 10.4.2.2.8. By Route of Administration
        • 10.4.2.2.9. By Drugs
    • 10.4.3. UAE Leukemia Therapeutics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Factor
        • 10.4.3.2.2. By Severity
        • 10.4.3.2.3. By Blood Cell
        • 10.4.3.2.4. By Age Groups
        • 10.4.3.2.5. By Sex
        • 10.4.3.2.6. By Treatment
        • 10.4.3.2.7. By Diagnosis
        • 10.4.3.2.8. By Route of Administration
        • 10.4.3.2.9. By Drugs

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. Novartis
    • 13.2.2. AbbVie
    • 13.2.3. Bristol-Myers Squibb
    • 13.2.4. Roche
    • 13.2.5. Amgen
    • 13.2.6. Gilead sciences
    • 13.2.7. Celgene
    • 13.2.8. Eisai
    • 13.2.9. AstraZeneca
    • 13.2.10. Incyte Corporation
    • 13.2.11. Johnson & Johnson
    • 13.2.12. Biogen
    • 13.2.13. Merck
    • 13.2.14. PerkinElmer
    • 13.2.15. Eli Lilly
    • 13.2.16. Abbott
    • 13.2.17. Sumitomo Dainippon Pharma
    • 13.2.18. Thermo Fisher Scientific
    • 13.2.19. Otsuka Holdings
    • 13.2.20. Astellas Pharma

14. Strategic Recommendations

15. About Us & Disclaimer